Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Update

Key Points

• Short interest in Shionogi & Co., Ltd. increased dramatically by 483.1%, totaling 304,400 shares as of August 31, up from 52,200 shares on August 15.
• The company's stock price is currently around $9.05, with a market capitalization of $15.40 billion and a P/E ratio of 15.29.
• Shionogi reported earnings of $0.16 EPS for the last quarter, exceeding expectations and indicating revenue of $672.90 million, which was lower than anticipated.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 304,400 shares, an increase of 483.1% from the August 15th total of 52,200 shares. Based on an average trading volume of 146,300 shares, the days-to-cover ratio is presently 2.1 days. Approximately 0.0% of the company's shares are sold short. Approximately 0.0% of the company's shares are sold short. Based on an average trading volume of 146,300 shares, the days-to-cover ratio is presently 2.1 days.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

SGIOY traded down $0.10 during trading hours on Friday, reaching $8.95. 50,649 shares of the company's stock traded hands, compared to its average volume of 68,831. The firm has a 50-day moving average price of $8.68 and a 200 day moving average price of $8.28. Shionogi & Co., Ltd. Unsponsored ADR has a 52-week low of $6.53 and a 52-week high of $9.14. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.13.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The business had revenue of $672.90 million for the quarter, compared to analysts' expectations of $719.55 million. As a group, research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.